Navigation Links
EntreMed Reports Second Quarter 2008 Financial Results
Date:8/6/2008

EntreMed to Conduct Update Call on Tuesday, August 12, 2008

ROCKVILLE, Md., Aug. 6 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today reported financial results for the three and six-month periods ending June 30, 2008.

(Logo: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO )

The Company reported a net loss for the second quarter of 2008 of ($9.6 million), or ($0.11) per share. This compares with a net loss of ($7.9 million), or ($0.10) per share, for the same period last year. For the first six months of 2008 the reported net loss was ($17.9 million), or ($0.22) per share as compared to ($15.6 million), or ($0.19) per share for 2007. The 2008 net loss for the three and six-month periods include a non-cash charge of $2.0 million, which represents a purchase price adjustment milestone triggered by the dosing of the first patient in a clinical trial for ENMD-2076, the lead molecule in our Aurora kinase program acquired from Miikana Therapeutics in January 2006.

The Company did not report any revenues for the first six months of 2008, although the Company believes that it will record royalty revenues in excess of $7 million on sales of Thalomid(R) by Celgene in the third and fourth quarters of 2008. As of June 30, 2008, EntreMed had cash and short-term investments of approximately $36 million.

Dane Saglio, EntreMed Chief Financial Officer, commented on the second quarter results, "During the second quarter of 2008, we recorded a $2.0 million non-cash charge resulting from the Company's dec
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. EntreMed Appoints Thomas H. Bliss as Senior Vice President of Corporate and Business Development
2. Dana-Farber Cancer Institute Commences Phase 1 Trial With EntreMeds Selective Kinase Inhibitor
3. EntreMed Will Not Seek Shareholder Approval for Reverse Stock Split at Annual Meeting
4. EntreMeds Kinase Inhibitor, ENMD-2076, Presented During AACR Special Session
5. EntreMed Receives Nasdaq Deficiency Notice
6. EntreMed to Present at BioCentury Future Leaders in the Biotech Industry Conference
7. EntreMed Announces 2008 Corporate and Clinical Program Priorities
8. EntreMed Reports Fourth Quarter and Year-End 2007 Financial Results
9. EntreMed to Present at BIO CEO and Investor Conference
10. EntreMed Presents Interim Results for Phase 2 Carcinoid Tumor Study
11. EntreMed Announces FDA Acceptance of IND Application for Aurora Kinase/Angiogenesis Inhibitor, ENMD-2076
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... Dec. 22, 2014  ( www.competitivehealth.com ) — Competitive ... medical bill review and advocacy service, has signed an ... WellCard Savings discount health services marketplace. 63% ... more than they expected to pay. As part of ... costs, WellCard Savings is pleased to offer medical bill ...
(Date:12/22/2014)... 22, 2014 Fertility Associates of Memphis ... Bank USA , a network of more than 20 ... partnership, patients have fast access to a national pool ... IVF . Fertility Associates of Memphis is the only ... treatment option. , Dr. William Kutteh , director ...
(Date:12/19/2014)... BioPlus Specialty Pharmacy (BioPlus), one ... of Nick Maroulis, Pharm.D. to the newly created position ... In this position, Dr. Maroulis will continue to manage ... of our multi-site pharmacies as the company expands. Dr. ... that time he has served in many different capacities ...
(Date:12/19/2014)... Dec. 19, 2014 Bina Technologies, Inc. (Bina, ... that they have been acquired by Roche (SIX: RO, ... privately held company that provides a big data platform ... (NGS) data for the academic and translational research markets. ... and will continue to focus on development of their ...
Breaking Biology Technology:WellCard Savings Announces CoPatient Medical Bill Review Service for Members 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 3BioPlus Specialty Pharmacy Promotes Dr. Nick Maroulis to Vice President of Specialty Pharmacy Services 2Bina Technologies is acquired by Roche. 2Bina Technologies is acquired by Roche. 3
... LEXINGTON, Mass., March 11 Indevus,Pharmaceuticals, Inc. (Nasdaq: ... the Cowen and Company 28th Annual Health Care Conference, ... conference is being held in,Boston, Massachusetts. The presentation will ... the Investors section of the Indevus website at, http://www.indevus.com ...
... March 11 Scott Lett, CEO of The,BioAnalytics ... make,scientific presentations at the Tucson Symposium on March ... Drug Discovery,Development and Clinical Diagnostics," will be attended ... biotechnology and,medical device industries., Dr. Lett,s invited ...
... STRASBOURG, France, March 11 Transgene,(Euronext Paris: FR0005175080) ... 2007 and outlook for 2008., "2007 was ... major,accomplishments: the signing of a partnership agreement with ... treatment of diseases caused by the,HPV virus, and ...
Cached Biology Technology:Indevus Pharmaceuticals to Present at Cowen and Company 28th Annual Health Care Conference 2Indevus Pharmaceuticals to Present at Cowen and Company 28th Annual Health Care Conference 3BioAnalytics Group CEO, Senior Scientist to Present at Tucson Symposium March 12-13 2Transgene in 2007: Partnership and Refinancing Position the Company for its Future Development 2Transgene in 2007: Partnership and Refinancing Position the Company for its Future Development 3Transgene in 2007: Partnership and Refinancing Position the Company for its Future Development 4Transgene in 2007: Partnership and Refinancing Position the Company for its Future Development 5Transgene in 2007: Partnership and Refinancing Position the Company for its Future Development 6Transgene in 2007: Partnership and Refinancing Position the Company for its Future Development 7Transgene in 2007: Partnership and Refinancing Position the Company for its Future Development 8Transgene in 2007: Partnership and Refinancing Position the Company for its Future Development 9Transgene in 2007: Partnership and Refinancing Position the Company for its Future Development 10Transgene in 2007: Partnership and Refinancing Position the Company for its Future Development 11Transgene in 2007: Partnership and Refinancing Position the Company for its Future Development 12
(Date:12/10/2014)... , Dec. 08, 2014 Research and ... the addition of the "Biometrics Market in ... http://photos.prnewswire.com/prnh/20130307/600769 ... projects such as rural banking and upgradation of ... trends witnessed in the market. Besides the aforementioned ...
(Date:12/5/2014)... MOUNTAIN VIEW, Calif. , Dec. 4, 2014 ... and safety has boosted investments in new testing ... products has also given rise to a range ... driven by the requirements of Generation Y, which ... digital technologies. As a result, product development strategies ...
(Date:12/4/2014)... BEACH GARDENS, Fla. , Dec. 3, 2014 ... management solutions, today announced that its DigitalPersona ® ... 4500 fingerprint readers have been deployed throughout First ... , South Carolina ... headquartered in Southern Pines, North Carolina ...
Breaking Biology News(10 mins):Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3
... is the payback on federal funding for scientific research? ... like the laser, GPS and MRI, companies like Google and ... also the scientists, engineers, doctors and teachers cultivated as ... most capable in the world. In its new "Innovators" ...
... continue to be debated and bandied about, real families who ... with expensive health care needs. These costs can be devastating ... family lives in Massachusetts or Maine. Advocates in many ... offer autism services at the same levels as other covered ...
... 16, 2012) Researchers at Rice University and Lockheed ... to make multiple high-performance anodes from a single silicon ... as an element in rechargeable lithium-ion batteries, laying the ... as commercial electronics and electric vehicles. The work ...
Cached Biology News:New video series highlights the people who fuel America's innovation pipeline 2New video series highlights the people who fuel America's innovation pipeline 3Study examines autism law, financial burdens 2Toughened silicon sponges may make tenacious batteries 2
...
From micro to giga sizes, from single prep to high-throughput, Invitrogen's range of plasmid purification kits offers superior performance to match the demands of your downstream application....
Request Info...
... GeneBLAzer cell-based assays utilize the ... of the negatively charged fluorescent beta-lactamase ... esters readily enter the cell, where ... converts them into their negatively charged ...
Biology Products: